Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)

Phase 3delpacibart etedesiranNeutral

AI Analysis

Summary

Novartis announced an update on the HARBOR Phase III study for delpacibart etedesiran in myotonic dystrophy type 1. No specific data or outcomes are provided in this ad hoc announcement.

Clinical Trial Data

Phase

Phase III

Importance:2/10

Sentiment:

0.00

Phase 3myotonic dystrophyHARBOR studyupdate

Related Companies

$NVS

Read the original article

Published by GlobeNewswire Pharma on September 8, 2026 5:00 AM

Read Original